Compare Stocks: IMNM, SMMT, CYTK, and NUVL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$75.07 -2.7%	$78.75	$32.89 ▼ $88.31	$9.35B	0.42	2.16 million shs	912,813 shs
IMNM Immunome	$22.77 +0.0%	$21.20	$8.66 ▼ $27.65	$2.58B	2.07	1.38 million shs	619,540 shs
NUVL Nuvalent	$123.96	$118.13	$71.13 ▼ $123.99	$9.79B	1.14	1.93 million shs	N/A
SMMT Summit Therapeutics	$13.14 +0.9%	$14.65	$12.25 ▼ $30.98	$10.49B	-1.23	3.97 million shs	1.39 million shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	0.00%	-4.47%	-10.82%	+21.75%	+110.22%
IMNM Immunome	0.00%	+2.48%	-3.60%	+0.13%	+114.92%
NUVL Nuvalent	0.00%	0.00%	+0.19%	+25.16%	+59.41%
SMMT Summit Therapeutics	0.00%	-4.69%	-15.56%	-19.18%	-51.90%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$75.07 -2.7%	$78.75	$32.89 ▼ $88.31	$9.35B	0.42	2.16 million shs	912,813 shs
IMNM Immunome	$22.77 +0.0%	$21.20	$8.66 ▼ $27.65	$2.58B	2.07	1.38 million shs	619,540 shs
NUVL Nuvalent	$123.96	$118.13	$71.13 ▼ $123.99	$9.79B	1.14	1.93 million shs	N/A
SMMT Summit Therapeutics	$13.14 +0.9%	$14.65	$12.25 ▼ $30.98	$10.49B	-1.23	3.97 million shs	1.39 million shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	0.00%	-4.47%	-10.82%	+21.75%	+110.22%
IMNM Immunome	0.00%	+2.48%	-3.60%	+0.13%	+114.92%
NUVL Nuvalent	0.00%	0.00%	+0.19%	+25.16%	+59.41%
SMMT Summit Therapeutics	0.00%	-4.69%	-15.56%	-19.18%	-51.90%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTK Cytokinetics	2.95	Moderate Buy	$99.90	33.08% Upside
IMNM Immunome	2.86	Moderate Buy	$33.17	45.69% Upside
NUVL Nuvalent	2.15	Hold	$127.73	3.04% Upside
SMMT Summit Therapeutics	2.44	Hold	$26.15	99.12% Upside

Current Analyst Ratings Breakdown

Latest IMNM, SMMT, CYTK, and NUVL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/24/2026	SMMT Summit Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00
7/24/2026	SMMT Summit Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$45.00 ➝ $38.00
7/24/2026	SMMT Summit Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $38.00
7/24/2026	SMMT Summit Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/23/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/21/2026	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$31.00
7/17/2026	CYTK Cytokinetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	IMNM Immunome	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	SMMT Summit Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/9/2026	IMNM Immunome	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTK Cytokinetics	$105.82M	88.27	N/A	N/A	($5.39) per share	-13.93
IMNM Immunome	$4.02M	642.13	N/A	N/A	$5.75 per share	3.96
NUVL Nuvalent	N/A	N/A	N/A	N/A	$15.95 per share	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTK Cytokinetics	-$784.96M	-$6.84	N/A	N/A	N/A	-784.02%	N/A	-52.86%	8/6/2026 (Estimated)
IMNM Immunome	-$212.39M	-$2.38	N/A	N/A	N/A	N/A	-51.15%	-47.32%	8/5/2026 (Estimated)
NUVL Nuvalent	-$425.38M	-$6.06	N/A	N/A	N/A	N/A	-40.11%	-35.43%	8/6/2026 (Estimated)
SMMT Summit Therapeutics	-$1.08B	-$1.12	N/A	N/A	N/A	N/A	-168.94%	-141.92%	10/19/2026 (Estimated)

Latest IMNM, SMMT, CYTK, and NUVL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CYTK Cytokinetics	-$1.63	N/A	N/A	N/A	$17.59 million	N/A
8/6/2026	Q2 2026	NUVL Nuvalent	-$1.44	N/A	N/A	N/A	$0.25 million	N/A
8/5/2026	Q2 2026	IMNM Immunome	-$0.5138	N/A	N/A	N/A	$0.17 million	N/A
7/23/2026	Q2 2026	SMMT Summit Therapeutics	-$0.2744	-$0.28	-$0.0056	-$0.28	$0.11 million	N/A
5/12/2026	Q1 2026	IMNM Immunome	-$0.60	-$0.48	+$0.12	-$0.48	$0.22 million	N/A
5/7/2026	Q1 2026	NUVL Nuvalent	-$1.35	-$1.39	-$0.04	-$1.39	$0.49 million	N/A
5/5/2026	Q1 2026	CYTK Cytokinetics	-$1.67	-$1.67	N/A	-$1.67	$8.52 million	$19.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTK Cytokinetics	N/A	4.21	4.21
IMNM Immunome	N/A	21.68	21.68
NUVL Nuvalent	N/A	16.14	16.14
SMMT Summit Therapeutics	N/A	6.96	6.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYTK Cytokinetics	N/A
IMNM Immunome	44.58%
NUVL Nuvalent	97.26%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
CYTK Cytokinetics	2.60%
IMNM Immunome	7.21%
NUVL Nuvalent	5.02%
SMMT Summit Therapeutics	83.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTK Cytokinetics	250	124.43 million	121.20 million	Optionable
IMNM Immunome	40	113.25 million	105.09 million	Optionable
NUVL Nuvalent	40	79.00 million	75.03 million	Optionable
SMMT Summit Therapeutics	110	797.75 million	131.63 million	Optionable

IMNM, SMMT, CYTK, and NUVL Headlines

Recent News About These Companies

Summit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Rating of "Hold" by Analysts

August 3 at 4:15 AM | americanbankingnews.com

Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Rating of "Hold" from Analysts

August 3 at 4:13 AM | marketbeat.com

Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches

July 31 at 2:00 PM | seekingalpha.com

What is HC Wainwright's Forecast for SMMT FY2026 Earnings?

July 31 at 1:44 AM | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Argenx Se (ARGX)

July 30, 2026 | theglobeandmail.com

What is HC Wainwright's Estimate for SMMT FY2026 Earnings?

July 29, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: HCA Healthcare (HCA), Summit Therapeutics (SMMT) and Neuphoria Therapeutics (NEUP)

July 29, 2026 | theglobeandmail.com

Summit Therapeutics (NASDAQ:SMMT) Hits New 12-Month Low - Time to Sell?

July 28, 2026 | marketbeat.com

Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm

July 27, 2026 | prnewswire.com

Summit Therapeutics Sees Unusually Large Options Volume (NASDAQ:SMMT)

July 26, 2026 | americanbankingnews.com

Summit Therapeutics (NASDAQ:SMMT) Earns Neutral Rating from HC Wainwright

July 25, 2026 | americanbankingnews.com

SMMT Stock Heads For Third Straight Weekly Drop – Analyst Tempers Expectations From Initial Lung Cancer Trial Survival Data

July 24, 2026 | msn.com

Traders Purchase High Volume of Call Options on Summit Therapeutics (NASDAQ:SMMT)

July 24, 2026 | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down After Earnings Miss

July 24, 2026 | marketbeat.com

SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus

July 24, 2026 | zacks.com

Summit Therapeutics (SMMT) Updates Phase III Survival Data, Is The Stock Still A Bargain?

July 23, 2026 | finance.yahoo.com

Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript

July 23, 2026 | seekingalpha.com

Summit Therapeutics Inc. 2026 Q2 - Results - Earnings Call Presentation

July 23, 2026 | seekingalpha.com

Summit Therapeutics Q2 Earnings Call Highlights

July 23, 2026 | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Releases Earnings Results, Beats Estimates By $0.08 EPS

July 23, 2026 | marketbeat.com

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026

July 23, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM, SMMT, CYTK, and NUVL Company Descriptions

Cytokinetics NASDAQ:CYTK

$75.06 -2.07 (-2.68%)

As of 02:15 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Immunome NASDAQ:IMNM

$22.76 +0.01 (+0.02%)

As of 02:15 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Nuvalent NASDAQ:NUVL

$123.96 0.00 (0.00%)

As of 07/16/2026

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Summit Therapeutics NASDAQ:SMMT

$13.14 +0.12 (+0.88%)

As of 02:15 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMNM, SMMT, CYTK, and NUVL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMNM, SMMT, CYTK, and NUVL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMNM, SMMT, CYTK, and NUVL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM, SMMT, CYTK, and NUVL Company Descriptions

Cytokinetics NASDAQ:CYTK

Immunome NASDAQ:IMNM

Nuvalent NASDAQ:NUVL

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMNM, SMMT, CYTK, and NUVL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMNM, SMMT, CYTK, and NUVL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMNM, SMMT, CYTK, and NUVL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM, SMMT, CYTK, and NUVL Company Descriptions

Cytokinetics NASDAQ:CYTK

Immunome NASDAQ:IMNM

Nuvalent NASDAQ:NUVL

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools